Information Provided By:
Fly News Breaks for November 6, 2019
MNTA
Nov 6, 2019 | 05:53 EDT
Wells Fargo analyst Yanan Zhu initiated coverage of Momenta Pharmaceuticals with an Outperform rating and $32 price target. The analyst views the company as attractively valued for the opportunity of its lead candidate nipocalimab in autoimmune diseases. The FcRn antagonist offers a favorable competitive position compared with other agents in this emerging category, Zhu tells investors in a research note.